Wave Life Sciences Ltd. (WVE) |
|
4.31 -0.16 (-3.58%)
|
01-27 16:00 |
|
Open: |
4.47 |
Pre. Close: |
4.47 |
|
High:
|
4.56 |
Low:
|
4.29 |
|
Volume:
|
267,740 |
Market Cap:
|
375(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:49:23 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 7.02 One year: 8.31 |
| Support: |
Support1: 4.21 Support2: 3.51 |
| Resistance: |
Resistance1: 6.01 Resistance2: 7.11 |
| Pivot: |
4.98 |
| Moving Average: |
MA(5): 4.52 MA(20): 5.37
MA(100): 4.49  MA(250): 3.27 |
| MACD: |
MACD(12,26): -0.3 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 10.6 %D(3): 12.8 |
| RSI: |
RSI(14): 37.1 |
| 52-week: |
High: 7.11 Low: 1.15 |
| Average Vol(K): |
3-Month: 728 (K) 10-Days: 480 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ WVE ] has closed above bottom band by 13.4%. Bollinger Bands are 5.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
4.57 - 4.59 |
4.59 - 4.62 |
|
Low:
|
4.22 - 4.25 |
4.25 - 4.28 |
|
Close:
|
4.26 - 4.31 |
4.31 - 4.36 |
|
Company Description |
|
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders. In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London. The company was incorporated in 2012 and is based in Singapore. |
Headline News |
Wed, 25 Jan 2023
Huntington's Disease Market to Witness Upsurge in Growth at a Tremendous CAGR of 18.4% During the Study Period (2019-2032), Predicts DelveInsight - Yahoo Finance
Wed, 25 Jan 2023
US Modernized Cosmetics Law's 'Weak' Safety Substantiation ... - HBW Insight
Tue, 24 Jan 2023
Update on Short Interest in Wave Life Sciences Ltd. (NASDAQ:WVE) - Best Stocks
Sun, 08 Jan 2023
TaiwanICDF partners with World Vision to guard maternal and child ... - ReliefWeb
Tue, 20 Dec 2022
WVE-N531 Showing Potential as Exon 53-skipping Therapy in Trial |... - Muscular Dystrophy News
Thu, 15 Dec 2022
Should You Accumulate Wave Life Sciences Ltd (WVE) Stock Thursday Morning? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
87 (M) |
|
% Held by Insiders
|
1.763e+007 (%) |
|
% Held by Institutions
|
16.2 (%) |
|
Shares Short
|
1,430 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-1.4843e+008 |
|
EPS Est Next Qtl
|
-1 |
|
EPS Est This Year
|
-3.72 |
|
EPS Est Next Year
|
-3.69 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-3 |
|
Return on Assets (ttm)
|
718.9 |
|
Return on Equity (ttm)
|
-50.8 |
|
Qtrly Rev. Growth
|
4.17e+006 |
|
Gross Profit (p.s.)
|
-1.26 |
|
Sales Per Share
|
0.72 |
|
EBITDA (p.s.)
|
-1.95 |
|
Qtrly Earnings Growth
|
-2.2 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-101 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
5.93 |
|
Price to Cash Flow
|
75.85 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
1.95e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
